BIODESIX, INC. (BDSX) Spending and interest coverage
- R&D / revenue · 12 months: Value 11.93%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.95%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -2.55×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 11.93% | Research and development expense / revenue. Period ending 2026-06-30. $12.28M ÷ $102.94M × 100 ≈ 11.93% |
| Stock-based compensation / revenue · 12 months | 3.95% | Share-based compensation / revenue. Period ending 2026-06-30. $4.06M ÷ $102.94M × 100 ≈ 3.95% |
| Interest coverage · 12 months | -2.55× | Operating income ÷ reported interest expense. $-20.61M ÷ $8.09M ≈ -2.55× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 12.28M USD | Research and Development Expense |
| Revenue | 102.94M USD | |
| Stock-based compensation | 4.06M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -20.61M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 8.09M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.28M | $102.94M | $4.06M | $-20.61M | $8.09M | 11.93% | 3.95% | -2.55× | Reported |
| 2026-03-31 | $12.42M | $96.10M | $4.28M | $-24.94M | $8.01M | 12.92% | 4.46% | -3.11× | Reported |
| 2025-12-31 | $12.00M | $88.50M | $4.14M | $-27.87M | $7.72M | 13.56% | 4.68% | -3.61× | Reported |
| 2025-09-30 | $11.54M | $80.17M | $4.33M | $-32.55M | $7.41M | 14.40% | 5.40% | -4.39× | Reported |
| 2025-06-30 | $11.10M | $76.56M | $4.79M | $-34.09M | $7.38M | 14.50% | 6.26% | -4.62× | Reported |
| 2025-03-31 | $10.39M | $74.46M | $4.97M | $-32.61M | $7.41M | 13.95% | 6.67% | -4.40× | Reported |
| 2024-12-31 | $9.56M | $71.32M | $6.64M | $-34.50M | $8.26M | 13.40% | 9.31% | -4.18× | Reported |
| 2024-09-30 | $9.03M | $65.56M | $6.45M | $-34.72M | (m) | 13.78% | 9.84% | (m) | (m) |
| 2024-06-30 | $8.43M | $60.90M | $5.89M | $-33.30M | $9.18M | 13.83% | 9.68% | -3.63× | Reported |
| 2024-03-31 | $8.78M | $54.85M | $5.73M | $-35.99M | $9.67M | 16.00% | 10.45% | -3.72× | Reported |
| 2023-12-31 | $9.99M | $49.09M | $5.37M | $-41.34M | $9.54M | 20.35% | 10.95% | -4.34× | Reported |
| 2023-09-30 | $11.66M | $44.03M | $6.37M | $-48.36M | $9.76M | 26.49% | 14.47% | -4.96× | Reported |
| 2023-06-30 | $12.70M | $41.64M | $6.58M | $-51.80M | $10.41M | 30.49% | 15.81% | -4.98× | Reported |
| 2023-03-31 | $13.15M | $40.72M | $6.90M | $-52.50M | $9.33M | 32.29% | 16.94% | -5.63× | Reported |
| 2022-12-31 | $13.10M | $38.21M | $5.96M | $-50.59M | $8.07M | 34.29% | 15.60% | -6.27× | Reported |
| 2022-09-30 | $12.39M | $35.83M | $5.15M | $-48.38M | $7.02M | 34.58% | 14.38% | -6.89× | Reported |
| 2022-06-30 | $12.71M | $31.25M | $5.37M | $-50.86M | $5.53M | 40.67% | 17.17% | -9.20× | Reported |
| 2022-03-31 | $12.67M | $32.19M | $4.54M | $-49.82M | $4.99M | 39.37% | 14.10% | -9.98× | Reported |
| 2021-12-31 | $12.79M | $54.51M | $4.94M | $-40.94M | $4.51M | 23.46% | 9.07% | -9.08× | Reported |
| 2021-09-30 | $13.04M | $74.31M | $7.23M | $-31.91M | $3.72M | 17.55% | 9.73% | -8.59× | Reported |
| 2021-06-30 | $12.46M | $76.97M | $5.95M | $-25.06M | $4.83M | 16.18% | 7.72% | -5.19× | Reported |
| 2021-03-31 | $11.24M | $69.33M | (m) | $-20.09M | $6.80M | 16.21% | (m) | -2.96× | Reported |
| 2020-12-31 | $10.82M | $45.56M | $3.71M | $-22.93M | $7.60M | 23.75% | 8.14% | -3.02× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $10.47M | $24.55M | $170.00K | $-26.74M | $3.01M | 42.64% | 0.69% | -8.89× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |